Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCRB00504
2016-03-30
Prospective
RGC Ref No.14111115
General Research Fund
Research Grant Council
Not applicable
Not Applicable
Lu, Hanna
G/F, Multi-centre,
Department of Psychiatry
Tai Po Hospital.
Tai Po
New Territories
Hong Kong
28314305
hanna19830213@gmail.com
Department of Psychiatry, The Chinese University of Hong Kong
Hong Kong
Linda Chiu Wa LAM
G/F, Multi-centre,
Department of Psychiatry
Tai Po Hospital.
Tai Po
New Territories
Hong Kong
85226076027
cwlam@cuhk.edu.hk
Department of Psychiatry, The Chinese University of Hong Kong
Hong Kong
Clinical Efficacy of Neuro-navigated repetitive Transcranial Magnetic Stimulation (rTMS) in the management of Depression in Major Neurocognitive Disorders– a single blind randomized control trial
Neuro-navigated repetitive Transcranial Magnetic Stimulation (rTMS) for depression in dementia
定位連環透顱磁力剌激對認知障礙症患者抑鬱徵狀的療效研究
Hong Kong
Yes
2015-04-27
Joint CUHK-NTEC Clinical Research Ethics Committee
2015.127-T
Major Neurocognitive Disorders
Other
repetitive Transcranial Magnetic Stimulation (rTMS)
Repetitive Transcranial Magnetic Stimulation (rTMS) is a safe and non-invasive brain stimulation approved by for the treatment of Major Depressive Disorder not satisfactorily responded to at least one type of antidepressant in the United States. The electromagnetic field leads to changes in neuronal activities by inducing action potentials along the cells. TMS has been used in the treatment of other neurological conditions including aphasia and neurological pain. There has also been some evidence to suggest that TMS, when combined with cognitive training, may exert positive effects on cognition in patients with Alzheimer’s disease (AD).
Magnetic stimulation
10 Hz, 30 trains and 1500 pulses per day
3 weeks
5 (once daily) treatment sessions per week
Sham Transcranial Magnetic Stimulation
Sham magnetic stimulation
Sham magnetic stimulation
3 weeks
5 (once daily) treatment sessions per week
Major Neurocognitive Disorder due to AD
Major Vascular Neurocognitive Disorder with small vessel disease
Cornell Scale for Depression in dementia (CSDD) with a rating of 7 or over
Past history of bipolar affective disorder or psychosis
Physically frail affecting attendance to TMS sessions
Already attending other brain stimulation therapies
History of major neurological deficit including history of major stroke, transient ischemic attack or traumatic brain injury
Significant communicative impairment
60
90
Both Male and Female
Interventional
Randomized
Participants would be individually randomized into either rTMS or sham TMS groups.
Placebo
Single-blind
Trial subjects
Parallel
Other
Non-drug intervention
2016-04-01
60
Not Yet Recruiting
Depressive symptoms
Cornell Scale for Depression in dementia (CSDD)
Third week; Sixth week; Twelfth week
Global cognitive function
Hong Kong Chinese version of Montreal Cognitive Assessment (MoCA)
Third week; Sixth week; Twelfth week
Neuropsychiatric symptoms
The Chinese Neuropsychiatric Inventory (NPI)
Third week; Sixth week; Twelfth week
Quality of life
Quality of Life – AD (QOL-AD)
Third week; Sixth week; Twelfth week
Serum BDNF levels
Brain-derived neurotrophic factor (BDNF)
Third week; Sixth week; Twelfth week
Adverse effects
A checklist of potential adverse effects associated with rTMS administration
Third week; Sixth week; Twelfth week
2016-03-30
|
|
|
|
---|---|---|---|
No documents yet. |